EDITORIAL

Molecular Targeting: the New Challenge in Lung Cancer Prevention

Ugo Pastorino

Correspondence to: Ugo Pastorino, M.D., Division of Thoracic Surgery, Istituto Europeo di Oncologia, Via Ripamonti 435, 20141, Milan, Italy (e-mail: ugo.pastorino{at}ieo.it).

Negative results from large-scale clinical trials (13) have resulted in a general skepticism toward lung cancer chemoprevention in humans. One has to consider, however, the enormous difficulties that clinicians encountered in their early attempts to counteract lung carcinogenesis, including attempts at intervention in individuals with decades of intense smoking exposure, or even during active smoking, using single chemopreventive agents that had limited proven efficacy and substantial side effects.

From this first generation of clinical trials, we have learned that retinoids may be active only at relatively high doses, where toxicity becomes a limiting factor, and their biologic effect, when clinically detectable, is not permanent (4). For example, neither the reversal of oral premalignancy nor the reduction in the incidence second primary cancers was sustained after retinoid treatment was discontinued (5,6). This phenomenon is indicative of phenotypic growth suppression without the concomitant eradication of neoplastic clones. Moreover, the number of individuals who had to be treated and tested for a long period of time was large given the relatively low underlying cancer incidence, which was only 0.5% per year in heavy smokers (1,2) and up to 2% per year in prior lung cancer patients (7). Nonetheless, the fundamental achievements of such chemoprevention trials were their contributions to our understanding of the preclinical phases of lung cancer and the identification of biomarkers relevant to field carcinogenesis (8). Knowledge of the molecular targets of chemopreventive agents represents the most valuable byproduct of otherwise "negative" studies and provides a basis for future research extending from early detection to pharmacologic intervention and gene therapy.

In this issue of the Journal, Soria et al. (9) report on the ability of N-(4-hydroxyphenyl)retinamide (4-HPR) to reduce the expression of human telomerase reverse transcriptase catalytic subunit (hTERT) in bronchial biopsy specimens obtained from heavy smokers enrolled in a double-blind chemoprevention trial (10). The authors reported that the reduction in hTERT messenger RNA (mRNA) expression after 6 months of 4-HPR treatment compared with baseline values in the 4-HPR arm or post-treatment values in the placebo arm was statistically significant when the analysis was based on biopsy sites (P = .01) but not when the analysis was based on individual participants (P = .37). Of interest, there was no relationship between the modulation of hTERT expression and other histopathologic features, such as the presence of squamous metaplasia or Ki-67 expression. Moreover, it appears from the first report of the same chemoprevention trial (10) that 4-HPR did not alter the levels of retinoic acid receptor (RAR)-{beta} mRNA in the bronchial epithelium as was observed after 13-cis-retinoic acid administration with a similar trial design (11). These results highlight a new and possibly RAR-independent molecular mechanism of action of 4-HPR against telomerase. In the chemoprevention trial (10), 4-HPR was unable to reverse metaplasia or dysplasia. However, it is possible that the significant reduction of serum retinol levels may have altered the overall effect of 4-HPR treatment.

Although several studies (1214) have explored the role of telomerase activation in lung cancer, the report by Soria et al. demonstrates that telomerase activation is a very frequent event in the bronchial epithelium of chronic smokers, regardless of its histopathologic appearance. Their results also suggest that hTERT may represent a specific molecular marker for the detection of preinvasive disease in early lung carcinogenesis and a potential intermediate biomarker to evaluate the efficacy of chemopreventive agents. It has long been clear that a single biomarker could not play the leading role in a process that was as heterogeneous as lung carcinogenesis. Rather, it appears more likely that a panel of molecular markers will be required to meet the goals of preclinical detection, to select high-risk individuals for chemoprevention, and to monitor intermediate time points for treatment effect.

In addition to hTERT expression, the expression of other promising biomarkers, such as p53 (15,16), p16 (17), Fhit (18), EGFR (19), and RAR-{beta} (20), needs to be concurrently validated in future intervention trials. Specifically, the triad of suppressor genes (i.e., p53, p16, and FHIT) offers the opportunity to explore new targeted intervention schemes by use of a gene therapy approach. A pilot study using adenovirus-mediated p53 gene transfer in advanced lung cancer has proven that such an approach is feasible and has limited toxicity (21). Preclinical studies (22) have shown that adenovirus-mediated p16 gene transfer may be effective for treating ovarian cancer and, perhaps, even more effective than adenovirus-mediated p53 gene transfer in inhibiting the growth of tumor cell lines in vitro and xenografts in vivo. Ji et al. (23) observed that adenovirus-mediated FHIT gene transfer into human lung cancer cell lines that have lost Fhit expression induced apoptosis and inhibited tumorigenicity and tumor growth in nude mice (23). More recently, gene therapy with adenoviral and adeno-associated viral vectors expressing Fhit has been applied to heterozygous Fhit(+/–) knockout mice treated with chemical carcinogens. Mice exposed to carcinogen while receiving viral vectors expressing the human FHIT gene were protected from tumor development (24). These studies suggest that gene transfer could be a novel clinical approach not only in the management of invasive disease but also in lung cancer prevention. Pulmonary delivery of gene therapy, alone or in combination with other agents, represents another challenge in lung cancer research.

In conclusion, the study by Soria et al. (9) represents an outstanding contribution to translational research in the field of chemoprevention. The value of hTERT expression and modulation should be further explored in future chemoprevention trials, possibly in combination with other molecular markers, such as those encoded by tumor suppressor genes.

REFERENCES

1 The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029–35.[Abstract/Free Full Text]

2 Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150–5.[Abstract/Free Full Text]

3 van Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 2000;92:977–86.[Abstract/Free Full Text]

4 Hong WK, Endicott J, Itri L, Doos W, Batsakis JG, Bell R, et al. 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315:1501–5.[Abstract]

5 Benner SE, Pajak TF, Lippman SM, Earley C, Hong WK. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J Natl Cancer Inst 1994;86:140–1.[Medline]

6 Pastorino U, Buyse M. Classic papers and current comments: adjuvant treatment of stage I lung cancer with high-dose vitamin A. J Clin Oncol. In press 2001.

7 Johnson BE. Second lung cancers in patients after treatment for an initial lung cancer. J Natl Cancer Inst 1998;90:1335–45.[Abstract/Free Full Text]

8 Papadimitrakopoulou VA, Hong WK. Biomolecular markers as intermediate end points in chemoprevention trials of upper aerodigestive tract cancer. Int J Cancer 2000;88:852–5.[Medline]

9 Soria JC, Moon C, Wang L, Hittelman WH, Jang SJ, Sun SY, et al. Effects of N-(4-hydroxyphenyl)retinamide on hTERT expression in the bronchial epithelium of smokers. J Natl Cancer Inst 2001;93:1257–63.[Abstract/Free Full Text]

10 Kurie JM, Lee JS, Khuri FR, Mao L, Morice RC, Lee JJ, et al. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 2000;6:2973–9.[Abstract/Free Full Text]

11 Xu XC, Lee JS, Lee JJ, Morice RC, Liu X, Lippman SM, et al. Nuclear retinoid acid receptor beta in bronchial epithelium of smokers before and during chemoprevention. J Natl Cancer Inst 1999;91:1317–21.[Abstract/Free Full Text]

12 Hiyama K, Hiyama E, Ishioka S, Yamakido M, Inai K, Gazdar AF, et al. Telomerase activity in small-cell and non-small-cell lung cancers. J Natl Cancer Inst 1995;87:895–902.[Abstract]

13 Albanell J, Lonardo F, Rusch V, Engelhardt M, Langenfeld J, Han W, et al. High telomerase activity in primary lung cancers: association with increased cell proliferation rates and advanced pathologic stage. J Natl Cancer Inst 1997;89:1609–15.[Abstract/Free Full Text]

14 Yashima K, Litzky LA, Kaiser L, Rogers T, Lam S, Wistuba II, et al. Telomerase expression in respiratory epithelium during the multistage pathogenesis of lung carcinomas. Cancer Res 1997;57:2373–7.[Abstract]

15 Sundaresan V, Ganly P, Hasleton P, Rudd R, Sinha G, Bleehen NM, et al. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene 1992;7:1989–97.[Medline]

16 Sozzi G, Miozzo M, Donghi R, Pilotti S, Cariani CT, Pastorino U, et al. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Res 1992;52:6079–82.[Abstract]

17 Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, Gabrielson G, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998;95:11891–6.[Abstract/Free Full Text]

18 Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C, et al. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998;58:5032–7.[Abstract]

19 Kurie JM, Shin HJ, Lee JS, Morice RC, Ro JY, Lippman SM, et al. Increased epidermal growth factor receptor expression in metaplastic bronchial epithelium. Clin Cancer Res 1996;2:1787–93.[Abstract]

20 Xu XC, Sozzi G, Lee JS, Lee JJ, Pastorino U, Pilotti S, et al. Suppression of retinoic acid receptor beta in non-small-cell lung cancer in vivo: implications for lung cancer development. J Natl Cancer Inst 1996;89:624–9.[Abstract/Free Full Text]

21 Swisher SG, Roth JA, Nemunaitis J, Lawrence DD, Kemp BL, Carrasco CH, et al. Adenovirus-mediated p53 gene transfer in advanced non-small-cell lung cancer. J Natl Cancer Inst 1999;91:763–71.[Abstract/Free Full Text]

22 Modesitt SC, Ramirez P, Zu Z, Bodurka-Bevers D, Gershenson D, Wolf JK. In vitro and in vivo adenovirus-mediated p53 and p16 tumor suppressor therapy in ovarian cancer. Clin Cancer Res 2001;7:1765–72.[Abstract/Free Full Text]

23 Ji L, Fang B, Yen N, Fong K, Minna JD, Roth JA. Induction of apoptosis and inhibition of tumorigenicity and tumor growth by adenovirus vector-mediated fragile histidine triad (FHIT) gene overexpression. Cancer Res 1999;59:3333–9.[Abstract/Free Full Text]

24 Dumon KR, Ishii H, Fong LY, Zanesi N, Fidanza V, Mancini R, et al. FHIT gene therapy prevents tumor development in Fhit-deficient mice. Proc Natl Acad Sci U S A 2001;98:3346–51.[Abstract/Free Full Text]



             
Copyright © 2001 Oxford University Press (unless otherwise stated)
Oxford University Press Privacy Policy and Legal Statement